NCT05645198

Brief Summary

Although the technique of radical gastrectomy had been advanced, postoperative complication can occur in 13\~25% of patient after radical gastrectomy. Pancreatic fistula and postoperative bleeding was reported as 2\~30% and 1\~2%, respectively. These complications often result fatal clinical course, so localized fibrin agent has been widely used at postoperative surgical bed after radical gastrectomy. Recently, natural origin polysaccharide-based carboxymetyl starch was approved as localized coagulative, no well-designed report was adressed in gastric cancer surgery field. This agent can formate physical barrier after application, thus can prevent microbleeding or pancreatic fistula after gastrectomy. THIS study is single-center, non-inferiority, open-label randomized trial that evaluates the effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2022

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 26, 2022

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

November 15, 2022

Completed
24 days until next milestone

First Posted

Study publicly available on registry

December 9, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2025

Completed
Last Updated

December 9, 2022

Status Verified

December 1, 2022

Enrollment Period

2.2 years

First QC Date

November 15, 2022

Last Update Submit

December 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Ratio of (patient who suffers from) pancreatic fistula

    Ratio of patient who suffers from pancreatic fistula

    Postoperative day 3

Study Arms (2)

Oozfix

EXPERIMENTAL

Arm with oozfix after gastrectomy

Drug: Oozfix

Greenplast

ACTIVE COMPARATOR

Arm with greenplast after gastrectomy

Drug: Greenplast

Interventions

OozfixDRUG

Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy

Also known as: Case group
Oozfix

Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy

Also known as: Control Group
Greenplast

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Gastric adenocarcinoma patient who underwent radical gastrectomy at Bucheon St. Mary's Hospital
  • Patient's Age is above 19 and less than 80
  • ECOG performance score : 0\~2

You may not qualify if:

  • Patient who underwent emergent gastrectomy
  • Patient who requires palliative gastrectomy due to advanced or metastatic carcinoma
  • Patient who requires operation due to other malignancy other than adenocrcinoma
  • Patient who underwent emergent gastrectomy or pancreatectomy before this study
  • Patient who underwent chemoradiation
  • Patient who took anticoagulants or with coagulopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BucheonStMarys

Bucheon-si, South Korea

RECRUITING

Related Publications (1)

  • Washio M, Yamashita K, Niihara M, Hosoda K, Hiki N. Postoperative pancreatic fistula after gastrectomy for gastric cancer. Ann Gastroenterol Surg. 2020 Sep 21;4(6):618-627. doi: 10.1002/ags3.12398. eCollection 2020 Nov.

    PMID: 33319151BACKGROUND

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Diagnosis-Related GroupsControl Groups

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Intervention Hierarchy (Ancestors)

Prospective Payment SystemReimbursement MechanismsInsurance, Health, ReimbursementFinancing, OrganizedEconomicsHealth Care Economics and OrganizationsEpidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Hayemin LEE

    Bucheon St. Mary's Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 15, 2022

First Posted

December 9, 2022

Study Start

October 26, 2022

Primary Completion

December 31, 2024

Study Completion

January 31, 2025

Last Updated

December 9, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations